Have a personal or library account? Click to login
UGT2B7 c.-161C>T polymorphism frequency in Croatian population Cover

References

  1. Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J, Shi J, Zhu L, Liu Z, Wang Y, Gao S, Hu M. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev 2017;49:105–38. doi: 10.1080/03602532.2017.1293682
  2. Lv X, Zhang J-B, Hou J, Dou T-Y, Ge G-B, Hu W-Z, Yang L. Chemical probes for human UDP-glucuronosyltransferases: a comprehensive review. Biotechnol J 2019;14(1):1800002. doi: 10.1002/biot.201800002
  3. Rowland A, Min e rs JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013;45:1121–32. doi: 10.1016/j.biocel.2013.02.019
  4. Kasteel EEJ, Darney K, Kramer NI, Dorne JLCM, Lautz LS. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors. Arch Toxicol 2020;94:2637–61. doi: 10.1007/s00204-020-02765-8
  5. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201–8. doi: 10.1124/dmd.104.000794
  6. Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 2005;25:521–44. doi: 10.1002/med.20035
  7. Dong D, Ako R, Hu M, Wu B. Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes. Xenobiotica 2012;42:808–20. doi: 10.3109/00498254.2012.663515
  8. Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 2014;141:92–116. doi: 10.1016/j.pharmthera.2013.09.002
  9. Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97–132. doi: 10.1016/j.pharmthera.2004.10.013
  10. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5:225– 32. doi: 10.1016/s0966-3274(97)80042-1
  11. Wang P, Lin X-Q, Cai W-K Xu G-L, Zhou M-D, Yang M, He G-H. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur J Clin Pharmacol 2018;74:433–42. doi: 10.1007/s00228-017-2395-z
  12. Shen ML, Xiao A, Yin SJ, Wang P, Lin XQ, Yu CB, He GH. Associations between UGT2B7 polymorphisms and cancer susceptibility: a meta-analysis. Gene 2019;706:115–23. doi: 10.1016/j. gene.2019.05.025
  13. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73–7. PMID: 9443856
  14. Bélanger A-S, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009;37:1793–6. doi: 10.1124/ dmd.109.027706
  15. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Bélanger A. 3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497–502. PMID: 10772627
  16. Wang H, Yuan L, Zeng S. Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 2011;82:1757–63. doi: 10.1016/j.bcp.2011.08.004
  17. Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004;75:223–33. doi: 10.1016/j.clpt.2003.10.006
  18. Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006;66:125–33. doi: 10.1158/0008-5472.CAN-05-2857
  19. Meech R, Hu DG, McKinnon RA, Mubarokah SN, Haines AZ, Nair PC, Rowland A, Mackenzie PI. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol Rev 2019;99:1153–22. doi: 10.1152/physrev.00058.2017
  20. Jarrar YB, Cha E-Y, Seo K-A, Ghim JL, Kim HJ, Kim DH, Lee SJ, Shin JG. Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation. J Lipid Res 2014;55:2334–42. doi: 10.1194/jlr.M051169
  21. Božina N, Ganoci L, Simičević L, Gvozdanović K, Domjanović IK, Fistrek Prlić M, Križ T, Borić Bilušić A, Laganović M, Božina T. Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arh Hig Rada Toksikol 2021;72:114–28. doi: 10.2478/aiht-2021-72-3549
  22. Sastre JA, Varela G, López M, Muriel C, González-Sarmiento R. Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia. Pain Pract 2015;15:22–30. doi: 10.1111/papr.12152
  23. Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit 2014;36:406–9. doi: 10.1097/ FTD.0000000000000012
  24. Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphateglucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004;75:223–33. doi: 10.1016/j.clpt.2003.10.006
  25. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW. 3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497–502. PMID: 10772627
  26. Wang H, Yuan L, Zeng S. Characterizing the effect of UDP glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 2011;82:1757–63. doi: 10.1016/j.bcp.2011.08.004
  27. Klarica Domjanović I, Lovrić M, Trkulja V, Petelin-Gadže Ž, Ganoci L, Čajić I, Božina N. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol 2018;84:2106–19. doi: 10.1111/bcp.13646
  28. Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003;73:566– 74. doi: 10.1016/S0009-9236(03)00053-5
  29. Singkham N, Towanabut S, Lertkachatarn S, Punyawudho B. Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 2013;69:1285–91. doi: 10.1007/s00228-012-1449-5
  30. Blanca Sánchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolas JM, Adín J, Shushtarian M, Armijo JA. UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 2010;32:177–84. doi: 10.1097/FTD.0b013e3181ceecc6
  31. Milosheska D, Lorber B, Vovk T, Kastelic M, Dolžan V, Grabnar I. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol 2016;82:399–411. doi: 10.1111/ bcp.12984
  32. Vrkić Kirhmajer M, Macolić Šarinić V, Šimičević L, Ladić I, Putarek K, Banfić L, Božina N. Rosuvastatin-induced rhabdomyolysis - possible role of ticagrelor and patients’ pharmacogenetic Profile. Basic Clin Pharmacol Toxicol 2018;123:509–18. doi: 10.1111/bcpt.13035
  33. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O’Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME; Genome Aggregation Database Consortium, Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581:434–43. doi: 10.1038/s41586-020-2308-7
  34. Genome Aggregation Database (gnomAD). UGT2B7 (rs7668258), 2022 [displayed 30 April 2022]. Available at https://gnomad.broadinstitute.org/variant/4-69962078-T-C?dataset=gnomad_r2_1
  35. The 1000 Genomes database. UGT2B7 (rs7668258) [displayed 30 April 2022]. Available at http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=4:69095860-69096860;v=rs7668258;vdb=variation;vf=94021737
  36. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample Resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res 2020;48(D1):D941–7. doi: 10.1093/nar/gkz836
  37. Bińkowski J MS. Gene-Calc [displayed 22 May 2022]. Available at http://www.gene-calc.pl
  38. van der Logt EM, te Morsche RH, Groenendaal N, Roelofs HM, de Metz M, van der Stappen JW, Nagengast FM, Peters WH. Genetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal c a n c e r risk . On co l R e s 2 0 0 9 ; 1 7 : 3 2 3 – 9 . do i : 10.3727/096504009787721203
  39. Zhao F, Wang X, Wang Y, Zhang J, Lai R, Zhang B, Zhou X. The function of uterine UDP-glucuronosyltransferase 1A8 (UGT1A8) and UDP-glucuronosyltransferase 2B7 (UGT2B7) is involved in endometrial cancer based on estrogen metabolism regulation. Hormones (Athens) 2020;19:403–12. doi: 10.1007/s42000-020-00213-x
  40. He B-X, Qiao B, Lam AK-Y, Zhao X-L, Zhang W-Z, Liu H. Association between UDP-glucuronosyltransferase 2B7 tagSNPs and breast cancer risk in Chinese females. Clin Exp Pharmacol Physiol 2018;45:437–43. doi: 10.1111/1440-1681.12908
  41. Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, Xiang CQ, Ma QW, Lu DR, Shen JH. An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 2005;85:502–6. doi: 10.1093/toxsci/kfi068
DOI: https://doi.org/10.2478/aiht-2022-73-3663 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 303 - 307
Submitted on: May 1, 2022
Accepted on: Nov 1, 2022
Published on: Dec 30, 2022
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Tamara Božina, Ena Karačić, Lana Ganoci, Silvija Čuković-Čavka, Jozefina Palić, Nada Božina, Livija Šimičević, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.